Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Study results confirm T-SPOT.TB performance is not affected by low CD4 count in HIV infected subject


Press Release
At Oxford Immunotec:
Dr Peter Wrighton-Smith, CEO
Tel: +44 (0)1235 442780
Fax: +44 (0)1235 442781
Email: info@oxfordimmunotec.com

Oxford Immunotec
94c Milton Park
Abingdon
Oxfordshire OX14 4RY, UK

Oxford Immunotec Inc,
2 Mount Royal Avenue,
Marlborough,
MA 01752

Oxford, UK; 23 May 2008 – Oxford Immunotec, the T cell measurement company, today announced the publication of a recent study, demonstrating the efficacy of using T-SPOT.TB to identify TB infection in HIV infected subjects.

In this study reported in Clinical and Experimental Immunology Clark et al showed that the T-SPOT.TB test was unaffected by CD4 count, having the same high sensitivity in patients with a very low CD4 count (less than 100 cells/μl) as those with a more normal CD4 count (above 400 cells/μl).

In the publication the authors conclude that “T-SPOT.TB is a useful assay to screen for TB infection even in HIV-1 patients with low CD4 counts and can be used in routine clinical practice”.

Commenting on the results, Dr Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec said, “this study confirms the role of T-SPOT.TB in the identification of TB infection in HIV infected subjects. This is particularly important as TB is one of the major causes of death in HIV infected subjects and the rates of TB/HIV co-infection are reaching epidemic proportions in some populations”.

– Ends –

Notes to editors:

About Oxford Immunotec
www.oxfordimmunotec.com
Oxford Immunotec, the T cell measurement company is based in Oxford, UK and Marlborough, MA. The Company develops and sells clinical diagnostic products based on its patented T-SPOT® technology, the first regulatory approved method for directly quantifying antigen-specific T cells.

T-SPOT is a simple and extremely accurate method of studying a person’s cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T cell response.

About T-SPOT®.TB
T-SPOT.TB is an in vitro T cell measurement assay used for diagnosing TB disease and latent TB infection and the first product from Oxford Immunotec using the T-SPOT technology. The product is extremely robust in that it gives a result every time and offers unrivalled and maintained sensitivity in high risk and immunocompromised patient groups. T-SPOT.TB is approved for sale in Europe, Canada & over 40 other countries worldwide and is designed to replace the 115 year old Tuberculin Skin Test. As such it offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market opportunity exceeding $1bn.

T-SPOT® is a trademark of Oxford Immunotec.

Journal Reference

Clark S, Martin S, Pozniak A, Steel A, Ward B, Dunning J, Henderson D, Nelson M, Gazzard B and Kelleher P. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease.
Clinical and Experimental Immunology. 1365-2249. 2007.


Publisher Contact Information:

Oxford Immunotec Ltd.
+44 (0)1235 442780
info@oxfordimmunotec.com

Company profile of Oxford Immunotec Ltd.
Past press releases of Oxford Immunotec Ltd..

Data


25,720
Tech investments
From our Online Data Service
16,652
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
May 17€4.0MBiopharmaceuticals
May 16€15.0MPayment software
May 16€4.0MInternet services
May 16€80.0MConsumer electronics
May 16€6.3MImaging
May 16€13.0MInternet services
May 16€34.5MBiotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.